DR. GERALD VINCENT QUINNAN, MD
Osteopathic Medicine at Manor Park Dr, Rockville, MD
License number
Maryland D0023794
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
14508 Manor Park Dr, Rockville, MD 20853
Phone
(301) 460-6625
Personal information
See more information about GERALD VINCENT QUINNAN at radaris.comName
Address
Phone
5576 Burnside Dr, Rockville, MD 20853
14508 Manor Park Ct, Rockville, MD 20853
14508 Manor Park Dr, Rockville, MD 20853
14630 Bauer Dr, Rockville, MD 20853
Rockville, MD
Professional information
Dr. Gerald V Quinnan, Rockville MD - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
14508 Manor Park Dr, Rockville 20853
(301) 460-6625 (Phone)
(301) 460-6625 (Phone)
Languages:
English
Dr. Gerald V Quinnan, Rockville MD - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
GERALD V QUINNAN MD
14508 Manor Park Dr, Rockville 20853
(301) 460-6625 (Phone)
14508 Manor Park Dr, Rockville 20853
(301) 460-6625 (Phone)
Certifications:
Internal Medicine, 1976
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Saint Louis University / School of Medicine
Graduated: 1973
U Hosp
Boston Medical Center
Saint Louis University / School of Medicine
Graduated: 1973
U Hosp
Boston Medical Center
Hiv-1 Envelope Glycoprotein Oligomer And Methods Of Use
US Patent:
8597658, Dec 3, 2013
Filed:
Nov 12, 2008
Appl. No.:
12/742272
Inventors:
Gerald Quinnan - Rockville MD, US
Christopher Broder - Silver Spring MD, US
Christopher Broder - Silver Spring MD, US
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Bethesda MD
International Classification:
A61K 39/00, A61K 39/21, C07K 14/00
US Classification:
4241881, 4241921, 530395
Abstract:
This invention relates to fusion polypeptides comprised of a trimerization domain fused to a non-membrane bound, non-cleaved gp160 polypeptide derived from the R2 HIV-1 Env glycoprotein and to compositions comprising the fusion polypeptides. This invention further relates to oligomers of the fusion polypeptides. This invention also relates to nucleic acids encoding the fusion polypeptides. This invention also relates to diagnostic and therapeutic methods using the fusion polypeptides. Further, this invention relates to the induction of cross-reactive neutralizing antibodies against HIV-1, and to immunogenic compositions for the prevention and treatment of infection by HIV-1.
Modified Hiv-1 Envelope Proteins
US Patent:
2012003, Feb 16, 2012
Filed:
Sep 9, 2005
Appl. No.:
11/662422
Inventors:
Christopher Broder - Silver Spring MD, US
Gerald Quinnan - Rockville MD, US
Gerald Quinnan - Rockville MD, US
Assignee:
THE HENRY M. JACKSON FOUNDATION - Rockville MD
International Classification:
A61K 39/21, C12N 15/49, A61K 38/16, C12N 15/63, A61P 31/18, C12N 1/21, C12N 1/19, C12N 5/10, C07K 16/10, C07K 14/16, C12N 1/00
US Classification:
4241881, 530350, 536 2372, 514 38, 4242081, 4353201, 435243, 43525233, 4352542, 435348, 435325, 435358, 435357, 435352, 5303894
Abstract:
The present invention relates to modified HIV-1 envelope proteins where one or more N-glycosylation sites have been deleted or modified, which produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these proteins. The invention also provides for nucleic acids, vectors, antibodies and pharmaceutical compositions that comprise said modified HIV-1 envelope proteins.
Hiv-1 Immunogenic Compositions
US Patent:
2011029, Dec 1, 2011
Filed:
Apr 7, 2011
Appl. No.:
13/081756
Inventors:
Gerald V. Quinnan - Rockville MD, US
Christopher C. Broder - Silver Spring MD, US
Gerald H. Voss - Grez-Doiceau, BE
Nathalie L. Mathy - Ramillies, BE
Christopher C. Broder - Silver Spring MD, US
Gerald H. Voss - Grez-Doiceau, BE
Nathalie L. Mathy - Ramillies, BE
International Classification:
A61K 9/127, A61P 37/04, A61P 31/18, A61K 39/21
US Classification:
424450, 4241881
Abstract:
The present invention encompasses vaccine and/or immunogenic compositions against HIV and their methods of use for the prevention and/or treatment of HIV infection and/or AIDS. The vaccine and/or immunogenic compositions may contain an isolated HIV protein or fragment thereof, an adjuvant comprising a Toll like receptor (TLR) 4 ligand, in combination with a saponin.
Modified Hiv-1 Envelope Proteins
US Patent:
2009023, Sep 17, 2009
Filed:
Aug 29, 2005
Appl. No.:
11/661210
Inventors:
Gerald Quinnan - Rockville MD, US
Fatim Cham - Germantown MD, US
Guido Van De Groen - Kontich, BE
Fatim Cham - Germantown MD, US
Guido Van De Groen - Kontich, BE
International Classification:
A61K 39/42, C07K 14/00, C07H 21/00, C12N 15/63, C12N 5/00, C12N 1/00, C12P 21/00, A61K 38/16, A61K 39/21, A61K 31/7052, C07K 16/00, A61P 31/18
US Classification:
4241601, 530350, 536 2372, 4353201, 435325, 435243, 435 691, 514 12, 4242081, 514 44 R, 5303871, 5303881
Abstract:
The present invention relates to modified HIV-1 envelope proteins which express epitopes that produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these epitopes.